Tamoxifen (TAM): The dispute goes on

Annali dell'Istituto Superiore di Sanita

Volumn 42, Issue 2, 2006, Pages 170-173

  Grilli, Sandro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Breast carcinoma; Chemoprevention; Excess risk of endometrial cancer risk; Pure antiestrogens; Tamoxifen

Indexed keywords

ANASTROZOLE; CYCLOOXYGENASE 2 INHIBITOR; ESTROGEN RECEPTOR; FENRETINIDE; FULVESTRANT; GOSERELIN; PROGESTERONE RECEPTOR; TAMOXIFEN;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; ENDOMETRIUM CANCER; HUMAN; MASTECTOMY; NONHUMAN; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; RISK; TAMOXIFEN;

EID: 33749848361     PISSN: 00212571     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-37.
2. Colacci A. Introduzione alla chemioprevezione. In: Amadori D, Grilli S (Ed.). Oncologia Genetica. Gaggiano (MI): Poletto Editore; 2001. p. 123-9.
3. Grilli S. Environmental carcinogenesis: tumour development and chemoprevention. Tumori 2001;87:S3-5.
4. Commissione Consultiva Tossicologica Nazionale (CCTN) (Italian Toxicology Advisory Committee). Rapporte dell'attività svolta nel 1990. Rossi L, Mucci N (Ed.). Tamoxifen. Roma: Istituto Superiore di Sanità; 1991. (Serie Rapporti Interni 91/1). p. 323-9.
5. Costa A. Breast cancer chemoprevention. Eur J Cancer 1993;29A:589-92.
6. Sargent LM, Dragan YP, Bahnub N, Wiley JE, Sattler CA, Schroeder P, Sattler GL, Jordan VC, Pitot HC. Tamoxifen induces hepatic aneuploidy and mitotic spindle disruption after a single in vivo administration to female Sprague-Dawley rats. Cancer Res 1994;54(13):3357-60.
7. Vancutsem PM, Lazarus P, Williams GM. Frequent and specific mutations of the rat p53 gene in hepatocarcinomas induced by tamoxifen. Cancer Research 1994;54(14):3864-7.
8. Zito R. Problems in breast cancer prevention and therapy by tamoxifen. J Exp Clin Cancer Res 1994;13:99-101.
9. Gasco M, Argusti A, Bonanni B, Decensi A. SERMs in chemoprevention of cancer. Eur J Cancer 2005;41(13):1980-9.
10. Beland FA, Marques MM, Gamboa da Costa G, Phillips DH. Tamoxifen-DNA adduct formation in human endometrium. Chem Res Toxicol 2005;18(10):1507-9; author reply 1509-11.
11. Bush TL, Helzlsouer KJ. Tamoxifen for the primary prevention of breast cancer: a review and critique of the concept and trial. Epidemiologic Reviews 1993;15:233-43.
12. Seachrist L. Restating the risk of tamoxifen. Science 1994;263:910-1.
13. Ross PJ, Powles TJ. Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials. Clin Breast Cancer 2001;2:33-6.
14. Colacci A. Chemioprevenzione nei gruppi a rischio. In: Amadori D, Grilli S (Ed.). Oncologia Genetica. Gaggiano (MI): Poletto Editore; 2001. p. 191-205.
15. Robertson JF. Selective oestrogen receptor modulators/new antioestrogen: a clinical perspective. Cancer Treat Rev 2004;30:695-706.
16. Smith RE, Good BC. Chemoprevention of breast cancer and the trials of National Surgical Adjuvant Breast and Bowel Projects and others. Endocr Relat Cancer 2003;10:347-57.
17. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J; ABCSG and the GABG. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455-62.
18. Cuzick J. Aromatase inhibitors in prevention - data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). Recent Results Cancer Res 2003;163:96-103.
19. Mokbel K. Risk-reducing strategies for breast cancer- a review of recent literature. Int J Fertil Women Med 2003;48:274-7.
20. Johansen AM. Breast cancer chemoprevention: a review of selective estrogen receptor modulators. Clin J Oncol Nurs 2005;9:317-20.
21. Kramer B, Brown P. Should tamoxifen be used in breast cancer prevention? Drug Saf 2004;27:979-89.
22. IARC Monographs on the evaluation of carcinogenic risks to humans. Tamoxifen. In: Some pharmaceutical drugs. Lyon: International Agency for Research on Cancer; 1996. Vol. 66. p. 253-365.